Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas-Reference-Cited by-同舟云学术

Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas

Published:2018-01-01 Issue:1 Volume:4 Page:93
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Toulmonde Maud¹,Penel Nicolas²,Adam Julien³⁴,Chevreau Christine⁵,Blay Jean-Yves⁶,Le Cesne Axel⁷,Bompas Emmanuelle⁸,Piperno-Neumann Sophie⁹,Cousin Sophie¹,Grellety Thomas¹,Ryckewaert Thomas¹⁰,Bessede Alban¹¹,Ghiringhelli François¹²,Pulido Marina¹³¹⁴,Italiano Antoine¹

Affiliation:

1. Department of Medical Oncology, Institut Bergonié, Bordeaux, France

2. Department of Medical Oncology, Centre Oscar Lambret, Bordeaux, France

3. Department of Pathology, Gustave Roussy, Villejuif, France

4. INSERM U981, Villejuif, France

5. Department of Medical Oncology, Oncopole Toulouse, Toulouse France

6. Department of Medical Oncology, Centre Leon Berard, Lyon, France

7. Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France

8. Department of Medical Oncology, Institut de Cancérologie de l’Ouest, Nantes, France

9. Department of Medical Oncology, Institut Curie, Paris, France

10. Department of Medical Oncology, Centre Oscar Lambret, Lille, France

11. Immusmol, Bordeaux, France

12. INSERM, Dijon, France

13. Unité de Recherche et d’Epidémiologie Cliniques, Institut Bergonié, Bordeaux, France

14. INSERM CIC 1401, Bordeaux, France

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Cited by 287 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas: a phase II trial;Nature Communications;2024-01-23

2. Role of Immunotherapy in Sarcomas;International Journal of Molecular Sciences;2024-01-19

3. Spatial analysis of NOS2 and COX2 interaction with T-effector cells reveals immunosuppressive landscapes associated with poor outcome in ER- breast cancer patients;2023-12-23

4. Immune checkpoint inhibitors in sarcomas: a systematic review;Immuno-Oncology and Technology;2023-12

5. The cross-talk between macrophages and tumor cells as a target for cancer treatment;Frontiers in Oncology;2023-11-14